Unlock stock picks and a broker-level newsfeed that powers Wall Street.

KOSDAQ - Delayed Quote KRW

HansBiomed Corporation (042520.KQ)

Compare
7,160.00
-10.00
(-0.14%)
At close: 3:30:30 PM GMT+9

Key Executives

Amounts are as of December 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
NameTitlePayExercisedYear Born
Seok-Bae Oh Chief Financial Officer and Managing Director -- -- 1971
Mr. Won-Gyun Kwon Senior MD & Director -- -- 1954
Guen Young Kim Chief Executive Officer -- -- --

HansBiomed Corporation

7, Jeongui-ro 8-gil
Songpa-gu
Seoul, 05836
South Korea
82 2 466 2266 https://www.hansbiomed.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
261

Description

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product that transplanted in a patient whose skin has been lost due to breast cancer; and SureDerm, an acellular dermal matrix. It also offers BELLAGEL, a breast prosthesis, internal, and gel-filled solution; MINT Lift, a PDO thread; EZ-Tcon solution; Lion HT/HN, a hair transplanter body/needle; and Scar Clinic, a scar management solution. The company was formerly known as Hans Medical Corp. and changed its name to HansBiomed Corporation in June 2000. The company was founded in 1990 and is headquartered in Seoul, South Korea.

Corporate Governance

HansBiomed Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 12, 2025 at 10:59 AM UTC - May 16, 2025 at 12:00 PM UTC

HansBiomed Corporation Earnings Date

Recent Events

September 27, 2019 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers